Mimer Medical, a Swedish pharmaceutical company, has taken a significant step forward in the journey of its spinach extract, Appethyl, towards securing a health claim related to satiety and weight management. This development is particularly noteworthy given the challenges and complexities of the supplement health claim substantiation process, which Professor Jan Bruhn, an eminent pharmacognosy expert and senior vice president of R&D at Mimer Medical, describes as "protracted and confusing."
Personally, I find it fascinating that Mimer Medical, despite its wealth of experience in the pharmaceutical industry, has had to navigate this intricate process. The team's dedication and perseverance are commendable, especially considering the high rejection rate of health claim applications by EFSA (European Food Safety Authority) between 2010 and 2020, where 55 out of 61 applications were rejected. The fact that they managed to get this far is a significant milestone, as Bruhn himself acknowledges.
What makes this story even more intriguing is the origin of Appethyl. It was the brainchild of Lund University professors Charlotte Erlanson-Albertsson and her husband Per-Åke Albertsson, who combined their expertise in weight management and photosynthesis nearly two decades ago. The extract is enriched with thylakoids, cellular membranes responsible for photosynthesis, which are believed to slow fat digestion and increase the production of satiety hormones GLP-1 and CCK.
However, the journey of Appethyl has not been without its hurdles. Swedish firm Greenleaf Medical, which previously licensed the manufacturing from Lund University, faced financial difficulties, including the loss of major investment, leading to its bankruptcy in 2023. This resulted in the ingredient disappearing from the market. Mimer Medical, recognizing the potential of Appethyl, especially in the thriving weight management market, purchased the IP and enrolled Professor Erlanson-Albertsson to revive the botanical.
One of the key advantages of Appethyl, as Bruhn points out, is its ability to impact two hunger hormones, providing a 'broader' and 'gentler' effect compared to natural GLP-1 agonist drugs. This unique feature could be a significant selling point in the competitive supplements market. The team's expertise in scientific substantiation and regulation, combined with the potential of Appethyl, makes it an attractive proposition for interested parties.
In my opinion, the success of Appethyl in securing a health claim could have far-reaching implications for the supplement industry. It could set a precedent for other natural ingredients with similar benefits, encouraging further research and development in this area. However, it also raises questions about the future of pharmaceutical companies in the supplement market, as they increasingly recognize the potential of natural ingredients.
Looking ahead, Mimer Medical's partnership with Clairfield International, an M&A firm, opens up opportunities for interested parties to get involved. The project's success could lead to significant financial gains, but it also highlights the importance of perseverance and the potential for innovation in the pharmaceutical industry. The story of Appethyl is a testament to the power of scientific research and the impact it can have on our health and well-being.
